Senner S, Eicher L, Aszodi N, Prinz J C, French L E, Wollenberg A
Klinik und Poliklinik für Dermatologie und Allergologie, Universitätsklinik München, Frauenlobstr. 9-11, 80337, München, Deutschland.
Klinik für Dermatologie I, München Klinik, München, Deutschland.
Hautarzt. 2020 May;71(5):383-386. doi: 10.1007/s00105-020-04565-8.
Dupilumab is a monoclonal antibody that binds to the common alpha chain of the IL‑4 and IL-13 receptor and blocks the Th2 signaling pathway, which plays a key role in the development of atopic dermatitis. We report on the case of a 40-year-old man, who developed histologically confirmed psoriasis after 6 weeks of dupilumab therapy. The arbitrary, abrupt stopping of the unusual, not guideline-based oral steroid therapy, together with the blockade of the Th2 signaling pathway by dupilumab were apparently the relevant trigger factors for the newly developed psoriasis in our patient.
度普利尤单抗是一种单克隆抗体，可与白细胞介素-4和白细胞介素-13受体的共同α链结合，并阻断在特应性皮炎发展中起关键作用的Th2信号通路。我们报告了一例40岁男性患者的病例，该患者在接受度普利尤单抗治疗6周后出现了组织学确诊的银屑病。随意、突然停用不寻常的、非基于指南的口服类固醇疗法，以及度普利尤单抗对Th2信号通路的阻断，显然是我们患者新发银屑病的相关触发因素。
